Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. The aim of this study was to assess the effect of a long-term course of high-dose i.v. pulses of calcitriol (CLT) on hyperparathyroid bone disease (HBD) and functiohal mass of parathyroid glands of chronically hemodialyzed uremic (CHU) patients. We prospectively studied nine CHU patients treated with CLT, 30 ng/kg/body wt, i.v., thrice weekly over a period of eight months. Plasma concentrations of intact parathyroid hormone (iPTH), bone GLA protein (bGLA) and bone isoenzyme of alkaline phosphatase (biALP) were sampled throughout. Transiliac bone biopsies were made before and after the start of CLT therapy. Double scanning scintigraphy of the neck with 20tTl-99Tc was made before, during and eight months after the start of the treatment. All patients but one, who later responded to higher than planned CLT doses, had significant decreases of plasma iPTH (F = 76; P < 0.0001; ANOVA). The mean pretreatment value of PTH was 966 160 (mean se) pg/mI and it had decreased significantly by the first week (T = 2.4, P < 0.04), and had fallen an average of 80% by the 35th week. Ionized plasma calcium concentration was 1.19 .01 mmol/Iiter which rose significantly (F = 13,5; P < 0.0001) by the 14th week to maximal peak levels, averaging 1.34
Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. The aim of this study was to assess the effect of a long-term course of high-dose i.v. pulses of calcitriol (CLT) on hyperparathyroid bone disease (HBD) and functiohal mass of parathyroid glands of chronically hemodialyzed uremic (CHU) patients. We prospectively studied nine CHU patients treated with CLT, 30 ng/kg/body wt, i.v., thrice weekly over a period of eight months. Plasma concentrations of intact parathyroid hormone (iPTH), bone GLA protein (bGLA) and bone isoenzyme of alkaline phosphatase (biALP) were sampled throughout. Transiliac bone biopsies were made before and after the start of CLT therapy. Double scanning scintigraphy of the neck with 20tTl-99Tc was made before, during and eight months after the start of the treatment. All patients but one, who later responded to higher than planned CLT doses, had significant decreases of plasma iPTH (F = 76; P < 0.0001; ANOVA). The mean pretreatment value of PTH was 966 160 (mean se) pg/mI and it had decreased significantly by the first week (T = 2.4, P < 0.04), and had fallen an average of 80% by the 35th week. Ionized plasma calcium concentration was 1.19 .01 mmol/Iiter which rose significantly (F = 13,5; P < 0.0001) by the 14th week to maximal peak levels, averaging 1.34 .02 mmol/liter. Changes in biALP were parallel to those of iPTH, while bGLA tended to increase immediately after the start of the therapy and to significantly decrease thereafter (T = 3.2; P < 0.01). There were significant decreases in all histomorphometric indices of HBD: the osteoid volume from 12 1.8 to 4.8 0.5% (P < 0.001), the osteoid surface from 45.7 3.2 to 27 5.2% (P < 0.001), the osteoblastic surface from 11.8 1.7 to 4.8 1.08% (P < 0.001), the eroded surface from 6.6 1.2 to 4.3 0.9 (P < 0.002), and the osteoclast surface from 2.2 0.3 to 1.2 0.3% (P < 0.009); there was even renornialization in some individual patients.
The bone formation rate was measured in six of the nine patients and was found to be lowered in all subjects who had had significant PTH decreases. The median of intensity of 201T1 uptake before therapy scored 7.8 (range 4 to 9.2) arbitrary visual units and decreased significantly (P < 0.001; Wilcoxon test) to 0.4 (0 to 8.25) after eight months of CLT treatment, suggesting significant decreases of the mass of the parathyroid glands. Thus, this study demonstrates that long-term therapy with high-dose i.v. pulses of CLT in CHU with proven HBD is able to consistently decrease their circulating iPTH to levels comparable with those of subjects with mild or no HBD and also to decrease the functional mass of their parathyroid glands. Further studies will ascertain what dose of CLT is required to maintain this state of euparathyroidism once the hyperparathyroidism has been reversed. Secondary hyperparathyroidism of chronic uremic patients is a severe endocrine disorder in which progressive enlargement of parathyroid glands results in excess parathyroid hormone (PTH) secretion, with an unwanted osteodestructive disease of the bone [1] . For several years the therapeutic approach to this syndrome has included restriction of phosphate intake, avoidance of negative external calcium balance and oral supplementation of synthetic analogues of calcitriol (CLT) [1, 21 , since hyperphosphatemia, hypocalcemia and 1,25 (OH) D3 deficiency were thought to promote parathyroid overgrowth with its attendant PTH oversecretion [1, 31. This combined therapeutic regimen, however, is often hard to handle as it is fraught with the difficulty of supplying CLT in doses large enough to lessen the PTH oversecretion without inducing excessive CLT-mediated intestinal absorption of calcium and phosphate, which could expose the patient to threatening hypercalcemia and extraosseous calciumphosphate salts precipitation [4] . Some years ago, Slatopoisky et a! intermittently administered high doses of CLT Lv. and proved these to be effective in inducing quick and consistent decreases in plasma PTH levels while avoiding excessive plasma calcium and phosphate increases [51. Since then, other studies have been reported [6] [7] [8] [9] which confirmed and extended these findings.
To date it is not known to what extent the PTH of uremic patients must be lowered, nor is it completely clear whether i.v. CLT treatment, in addition to lowering plasma PTH, also considerably improves the PTH-mediated osseous lesions and reduces the mass of parathyroid glands. We therefore undertook a longitudinal prospective study in a group of uremic patients with secondary hyperparathyroidism who were treated with i.v. CLT for eight months. Plasma PTh (iPTH), bone GLA protein (bGLA) and bone isoenzyme of alkaline phosphatase (b1ALP) were sampled throughout. Functional parathyroid mass was assessed serially by double scanning scintigraphy, while bone histomorphometry by transiliac bone biopsy was evaluated before the start and eight months after the beginning of i.v. CLT therapy.
Methods

Patients
Subjects were selected from a cohort of nearly 130 subjects currently treated at the Dialysis Unit of our Division of Nephrology. Exclusion criteria were: previous kidney grafting and/or prolonged use of steroids, past assumption of large amounts of aluminum salts, positive deferoxamine test indicating aluminum overload, average plasma total calcium (TCa) concentration exceeding 10.5 mg/dl and serum phosphate (SPhOS) higher than 6.5 mg/dl. Inclusion criteria were: average plasma iPTH concentration 6 times the upper normal limit, total ALP (TALP) exceeding the upper normal value by 50%, and radiological findings of hyperparathyroid bone disease (HBD). Of the twelve patients initially selected following these criteria, one was given a transplant, one was switched to peritoneal dialysis and the other died from myocardial infarction. The nine patients who were finally selected were four men and five women, aged 33 to 70 years. One of them had been parathyroidectomized two years before. Subjects had been on hemodialysis for 4 to 11 years and were dialyzed with bicarbonate three times a week against a dialysis bath with a calcium concentration of 3.5 mEq/liter. All were taking calcium acetate as the phosphate binder and had been on standard oral CLT, 0.25 daily or 0.5 jg every other day, for at least four years. None of them took cardiovascular or anticonvulsivant drugs. No patient took oral CLT treatment for at least three months prior to the study. During this period, serial measurements of some basal biochemical parameters were made. Furthermore, all subjects had their dietary intakes of calcium and phosphate formally assessed by dietary interviews and two-day diet diaries, with weighing of the foods. During the same period the subjects were switched to a dialysis bath containing 3 mEqlliter of calcium. Transiliac biopsy of the bone, after informed consent was given, and scintigraphy of parathyroid glands were made within ten days before starting i.v. CLT treatment. CLT was started at a dose of 30 nglkg/body wt (corresponding to a total dose of 2.1 tg for a 70kg subject), thrice weekly, at the end of each hemodialysis session. Plasma samples for ionized calcium (ICa), TCa, SPhOS, TALP and iPTH were drawn weekly, while bGLA and biALP were sampled about every 45 days. Parathyroid imagings were repeated after three to four months and after eight months, while bone biopsies were repeated eight months after the start of CLT therapy. During the study a series of criteria to prevent the onset of both hypercalcemia and hyperphosphatemia were used. As soon as predialysis ICa reached a value 1.35 mmol/liter, patients were switched to dialysis baths with 2.5 mEq/liter of calcium. On persistence of hypercalcemia the CLT dose was halved for a week, and then was discontinued until the ICa reached a value 1.30 mmollliter, at which time the initial dose was resumed. Following the onset of hyperphosphatemia ( 6 mg/dl), oral calcium acetate was increased up to a maximum of 6 g a day and, when necessary, aluminum hydroxide, up to a maximum of 2 g a day was allowed for only ten days. If these interventions were ineffective CLT was stopped.
Assays and measurements
The intact (1-84) PTH was measured by an IRMA (INCSTAR Corp., Stillwater, Minnesota, USA). The normal range in our laboratory is from 10 to 55 pg/mI. Intra-and interassay coefficients of variation were 3.5 and 6.8%. Bone Gla protein was measured by a radioimmunoassay (CIS; Bio International, France); the normal range is 1 to 14 g/dl, intraassay variation 5%, interassay variation 6.8%. The biALP was determined by a photometric assay, according to the method of Rosalky and Foo [101; normal values in our laboratory range from 20 to 150 lU/liter. Serum ionized calcium was determined by an ICA 1 ionized calcium analyzer (Radiometer A/S, Copenhagen, Denmark). Serum aluminum was measured by fiameless atomic absorption spectrophotometiy, while TCa, Phos, and TALP were measured by routine laboratory autoanalyzers. Transiliac bone samples were taken five days after completing double bone labeling (2 days on, 16 days off, 2 days on demethyl-chlortetracycline, 600 mg a day) with a Jamshidi trocar with an internal diameter of 4 mm. The specimens were processed according to procedures previously reported [11] , which also included evaluation of bone aluminum deposits by the aurin tricarboxylic acid method [12] . Quantitative histological analysis was accomplished with the aid of a semiautomatic image analyzer (Videoplan-Kontron, MUnchen, Germany) and the histomorphometric parameters expressed according to the standardized nomenclature [13] , without knowledge of the corresponding biochemical and clinical findings. The static indices of bone formation considered were: the osteoid volume (OV/BV%), expressed as a percent of the trabecular bone volume; the osteoid surface (OS/BS%) expressed as a percent of the trabecular bone surface; the osteoblastic surface (ObS/BS%), as a percent of trabecular bone surface osteoid lined by cuboidal osteoblasts and the osteoid thickness in m. As static indices representative of bone resorption, we measured: the eroded surface (ES/BS%), which is the percent of trabecular bone surface with Howship lacunae; the osteoclast surface (Oc.S/BS%), which is the fraction of trabecular bone surface lined by osteoclasts and the number of osteoclasts per m2 of tissue section, The dynamic parameter of bone formation (BFR) in tm3/tm2/day, was calculated by multiplying the measured rate of mineral apposition by the total tetracycline-labeled mineralizing surface. For comparisons with normal values, data for static parameters were collected from necroscopic bone samples of fifty people dying suddenly or in violent accidents, matched for sex and age and coming from to the same geographical area of our subject study group. Parathyroid masses were localized by Thallium-201 (201T1) and Technetium 99m (99TC) subtraction scintigraphy [14] , with data acquired by a gamma-camera with collimator connected to an on-line computer. The scannings collected were read thrice by a very experienced operator, who was unaware of the subject's identity, the order in which the scintiscans had been performed, or when the scintimaps had been obtained from the same subject.
Calculation and statistics
The intensity of the 201T1 uptake by the parathyroid glands was evaluated by averaging three consecutive estimates of the reader, who labeled an ungraduated visual analogic scales from arbitrary units (AU) [15] scoring from 0 (no uptake) to 10 (very high uptake). To assess the reproducibility of these readings, we calculated the percentage differences between the middle value and the lower and the higher values of each reading. These percentage differences were averaged, and the standard deviations of this average and the 95% confidence limits (mean 2 SD) were calculated. Changes in 201'fl uptake (positive or negative) exceeding these values were considered to not be random variability but to be significant.
Results are presented as means SE. 15 3 pg/liter. The assessed dietary intakes of calcium and phosphate were 504 50 mg/day (range 247 to 742) and 1073 87 mg/day (range 700 to 1543), respectively. The mean daily intake of calcium acetate during the eight month study period was 5.2 0.18 g (range 4.5 to 6). To prevent the onset of overt hypercalcemia, six of the nine patients had to be switched to low-calcium dialysis baths two to six months after starting i.v. CLT therapy. To prevent hyperphosphatemia, shortterm courses of low doses of aluminum hydroxide were required by all subjects. The number of aluminum administration cycles ranged from 1 to 9. Intravenous CLT was withheld for seven of nine patients for a period of one to four weeks. At the end of the study period, the calculated weekly i.v. CLT dose for each patient averaged 5.4 0.2 j.g (3.9 to 6 j.g).
One patient did not respond to the planned i.v. CLT; however, he did respond eight months later after stepped increases in the dose (see below). Sequential changes in iPTH concentrations and in ICa in the eight patients who responded earlier are shown in Figure 1 . The mean value of iPTH soon after oral CLT was stopped was 808 98 pg/mI and tended to increase, but insignificantly, during the following three months. The baseline iPTH immediately before the start of i.v. CLT therapy was 966 160 pg/ml (416 to 1727) and it decreased significantly (F = 76; P < 0.0001; ANOVA) and continuously thereafter. Plasma concentrations of the hormone declined from the first week (T = 2.4; P 0.04) to the 22th week, and then flattened off, reaching a final level of 153 38 pg/ml (60 to 332). The average pretreatment value for ICa was normal (1.19 0.01 mmollliter, normal range: 1.15 to 1.30 mmol/liter). After the start of i.v. CLT therapy, ICa levels fluctuated slightly within normal values, then tended to rise to a level significantly higher than baseline after week 14 (T = 2.28; P < 0.05). From this time onward, ICa continued to rise but average peak levels never exceeded 1.34 mmollliter. Table 1 reports the changes of plasma concentrations of the other biochemical and humoral parameters that were sampled throughout the study. There were significant decreases in plasma TALP concentrations (F = 109; P < 0.0001; ANOVA) by the third week (T = 2.9; P < 0.02) and in biALP by the seventh week, the final Asterisks indicate significance (*P < 0.05; **P <0.01) versus time 0. Dashed area is the normal iPTH range. CLT were found to be higher, although insignificantly, than the baseline because there were opposite changes in plasma concentrations of the protein in the group, since it tended to rise in five patients and decrease in the others (data not shown). From this time onward, however, there were concordant decreases in bGLA in the whole group, so that the changes became significant by the four month (T = 3.2; P < 0.01). Final values of bGLA of all subjects (range 23 to 84 g/dl) remained over the upper normal limit of the protein assay in our laboratory. The TCa remained nearly unvaried until the nineteenth week then started to increase significantly (T = 2.6; P = 0.03), remaining higher than the basal level. The average baseline SphO. concentration was higher than normal and remained essentially unchanged thereafter. Figure 2 shows the patterns of iPTFI, biALP and ICA in the subject who did not respond to the standard treatment. Neither his iPTH nor his biALP decreased over eight months on i.v. CLT treatment. It was therefore decided to increase his i.v. CLT dose to 40 ng/kg body wt and then to 50 ng/kg body wt, thrice a week. As can be seen, this latter dose resulted in sharp decreases of both iPTH and biALP concentrations, without inducing any considerable increase in ICA plasma concentration.
Analytical details of the most important histomorphometric parameters measured before and eight months after starting the i.v. CLT therapy are given in Table 2 . Three of nine patients showed no evidence of positive tetracycline-labeled surfaces in the examination of the first bone biopsy. Scrutiny of each individual case revealed that two patients did not closely adhere to the advices for correct tetracycline assumption, while the third patient admitted he did not take the drug. Static histomorphometric indices of bone formation and resorbtion were all far above the upper limit of the range for the control subjects (Table 2) . After eight months of treatment, with the exception of the patient who did not respond to the therapy, these indices became lower in all subjects, to complete normalization in some of them. These changes were all statistically significant when the "non-responder" patient was excluded from the analysis. Also significant were the changes in other parameters of the histomorphometric examination, including the osteoid thickness 14 0.6 m after therapy compared to 20.5 0.8 (T = 11.7; P = 0.001), and the number of osteoclasts per m3 of tissue section (0.9 0.2 vs. 2.2 0.5; T = 3.6; P < 0.008). Overall, changes in static histomorphometric parameters were parallel to those in plasma iPTH (Figs. 3 and 4 (Table 2) . Stainable aluminum bone deposits were not seen either before or after treatment. Fourteen putative parathyroid glands were identified by 201'fl 99TC subtraction scintigraphy of the neck in eight patients, while no glands were found in the parathyroidectomized patient ( Table 3 ).
The calculated intra-reading variation for this series of basal readings was 1.18 11%. Thus, the intrinsic variability of each reading was considered to range from -21 to +23% (mean 2 SD).
After eight months of therapy both the number and the intensity of uptake remained almost the same in three patients, including the one who did not respond to the therapy, while the other had complete disappearance of the glands or great and significant attenuation of the uptake (Table 3) . Discussion Treatment of the osteodystrophic uremic syndrome includes control of serum calcium and phosphate and administration of PTH, pg/mi CLT analogues [1, 3] . The mainstay of the therapy, however, is CLT supplementation, since maintenance of normal serum calcium and phosphate concentration by oral calcium loads and intestinal binding of dietary phosphate do not prevent PTH oversecretion [16] . For many years, CLT analogues have been administered by continuous daily oral assumption [4] . This method of administration, although frequently effective in both lowering plasma PTH and in improving bone lesions [17] , is often hindered by the onset of hypercalcemia [1, 4] . In 1981, Madsen, Olgaard and Ladefoged demonstrated that circulating PTH levels of patients with acute renal failure could be decreased within hours following repeated i.v. injections of high doses of CLT, without any measurable increases in plasma calcium concentrations [18] . Some years later, Slatopoisky et al gave i.v. CLT boluses three times a week to a group of chronic uremic patients, and observed considerable decrease of their plasma PTH concentrations before the serum calcium changed [5] . These findings, besides revealing an inhibitory effect of CLT on PTH secretion Means values refer to patients n.1 to n.8. Ranges (n.r.) for static indices of fifty sex-and age-matched normal subjects are also indicated. Significance (after vs. before, with P at least < 0.009) independent of changes in plasma calcium, also opened the way to a new method to administer CLT therapy by which PTH inhibition could be obtained at lower risk of hazardous hypercalcemia.
As a matter of fact, many papers appearing thereafter have confirmed that intermittent high doses of CLT given either i.v. [6] [7] [8] [9] or as oral boluses [19] induce large decreases in plasma PTH with only minor changes in plasma calcium concentrations. Most of these studies, however, were aimed at ascertaining whether and to what extent plasma iPTH could be lowered, or to elucidate the effect of this type of therapy on the reciprocal relationships between changes in ambient calcium and parathyroid hormone release. No studies were specifically aimed at ascertaining to what extent plasma iPTH must be lowered in order to induce considerable improvement in bone lesions and to possibly reduce the parathyroid functional mass. We, therefore, prospectively studied a group of chronically hemodialyzed uremic patients already deemed to have secondary hyperparathyroidism refractory to conventional continuous daily oral CLT therapy. The main criterion for inclusion in the study was an iPTH concentration 6 times the upper normal value, because it had already been observed that concentrations of intact PTH above this limit are representative of an underlying severe HBD [201. Before entering the study the subjects were also screened to exclude occult body aluminum overload, since decreases of circulating iPTH in these subjects could theoretically precipitate an aluminum-associated bone disease [21] . All of the patients enrolled had normal plasma calcium and "controlled" serum phosphate concentrations, but either their iPTH or TALP and biALP concentrations were greatly elevated, indicating a severe degree of HBD.
While it seems clear that intermittent peak increases in plasma CLT concentration are more effective in decreasing plasma iPTH, than the same amount of CLT given continuously over a longer time period [22] , there is still debate as to whether oral or i.v. boluses are to be preferred [23] . Theoretically, the i.v. administration would have the advantage of avoiding excess hypercalcemia resulting from overexposure of the intestinal CLT cell receptors to CLT, and of achieving high peak increases with occupancy of parathyroid CLT receptors by circumventing the hepatic CLT degradation [4, 23, 24] .
In our study, we planned to administer the drug i.v., since it has the obvious clinical advantage of being strictly supervised [23] . Problems of compliance or correct adherence to the scheduled prescription may be causes of therapeutic failure [23, 25] even in patients like ours, who were willing to adhere to the medical prescription. The CLT dose we used was 2.1 g/70 kg/body wt, since in the experience of one of us (D.R.) a dose lower than this did not result in overall PTH and TALP decreases in a large dialysis population group [261. Such a high dose of CLT, however, might cause hypercalcemia, which would hinder continuing the CLT therapy. This was why we used a phosphate chelating regimen, in which calcium acetate was combined with intermittent administration of aluminum hydroxide. In a previous study, administration of doses of aluminum hydroxide up to 30 mg/kg over one year did not significantly increase bone aluminum content in a group of young uremic patients treated with oral CLT [27] . In our patients, the cumulative daily intake of aluminum hydroxide over the entire study period ranged from 70 to 700 mg, corresponding to doses of ito 10 mg/kg for a 70 kg subject. Thus, even though one cannot disregard the potentially toxic effects of aluminum-containing phosphate binders, we feel it is unlikely that combined therapy with i.v. CLT and aluminum hydroxide in doses as low as those we have used might have had significant adverse effects in adult uremics. In our subjects, with the exception of the patient who later "responded" to higher doses, the average planned CLT dose administered i.v. thrice weekly over an eight month period caused a sharp decrease in iPTH from the first week and continuing until the fourteenth week. At this time the average decrease in iPTH was 61%, with no significant changes in either Ica or TCa in the meantime. From this time onwards, ICa increased slightly and PTH decreased further to an average of less 23%. Prevention of hypercalcemia with low calcium dialysis bath [28] and chelation of phosphate with combined calcium acetate and low-dose aluminum hydroxide [29] allowed us to administer a total CLT dose probably higher than those in previously reported studies. This is the likely explanation for such an impressive calcium independent PTH-inhibitory effect of i.v. CLT, which to our knowledge is one of the largest so far reported. These findings are strong support for previous contentions of the outstanding role of CLT deficiency in inducing pathologic PTH secretion of chronic uremic patients [5, 6, 24] , Parathyroid cells have stereospecific receptors for CLT similar to those found in intestine and bone [30] . CLT regulates the density of its receptors by increasing the expression of the CLT mRNA receptors gene. Occupancy of these receptors by the sterol leads to selective decrease of PTH mRNA synthesis [30] . Therefore, chronic deficiency of CLT due to defective production by the failing kidney might result in increased PTH synthesis, since low levels of CLT are delivered in proximity to the parathyroid receptors and the glandular density of these receptors is decreased. As a matter of fact, in chronic uremia, CLT receptors have been found to be lowered [31] , so that supraphysiological levels of circulating CLT were required to overcome the abnormal PTH mRNA synthesis in uremic rats [32] .
In chronically hemodialyzed uremic patients with long lasting secondary hyperparathyroidism, both nodular and diffuse-type parathyroid hyperplasia have been described [33] . The nodular tissue consists of clusters of actively proliferating parathyroid cells and gland weight is heavier and density of CLT receptors is lower than for the diffuse-type hyperplastic tissue [33] . In our study, one patient had a very high circulating iPTH level which was not lowered until nearly double the initial CLT dose was used (Fig. 2) .
In this subject, the changes in plasma ICa were quite similar to those already observed in the responder patients as a whole, so that a major contribution of ICa to induction of such a sharp decrease in iPTH concentration can be excluded. Lesser density of parathyroid CLT receptors in this patient is a more likely explanation for the initial glandular resistance to the PTH-lowering property of the sterol, which became evident only when very high doses were given. Whatever the mechanism, to a clinician who is interested in the overall therapeutic effect, it is important to know whether the administration of pharmacological doses of CLT not only lower circulating PTH but are also able to improve its untoward osseous effects, Classically described histological features of HBD include increased numbers of osteoblasts, appearance of woven osteoid and increase in bone formation rate [34] . In our patients, all static indices of bone formation and bone resorption were far above the upper limits of our normal control group. Furthermore, in those subjects who had positive tetracycline-labeled surfaces, the calculated BFR was found to be higher than the upper limit already reported for a normal population [35] . Eight months of ix. CLT therapy caused all these indices to decrease in each patient, with normalization of some parameters in some of them. These findings are in keeping with those already reported in the only study we know of the osseous effects of long-term i.v. CLT therapy in chronically dialyzed uremics [7] .
However, there are some differences between our study and that previous study which deserve some comment. In the study of Andress et al [7] , there was a significant decrease of the osteoid surface covered by osteoblasts, no change in the amount of osteoid tissue and a worsening of osteoclastosis in four of eleven patients. Furthermore, there was no significant decrease in PTH, as measured by the C-terminal assay, while the alkaline phosphatase, although significantly lowered, did not normalize. These findings might cast some doubt as to whether this therapy was indeed completely successful in those patients [36] . In our study we used a low-calcium dialysate bath to prevent the onset of hypercalcemia that would have hindered our efforts to administer an i.v. dose of CLT as large as possible. In the study of Andress et al, higher concentrations of calcium in the dialysate were used and there were frequent episodes of hypercalcemia. Thus it is possible that in that study, in the face of recurrent hypercalcemia, that average doses of CLT lower than ours were infused, which accounted for the apparently less successful therapy of those patients. In our patients, to be certain that bone findings did indeed reflect bone PTH activity, we attempted to eliminate such confounding variables as body aluminum overload [21, 34] . In the study of Andress et al, BFR was decreased in all patients, although some static osseous indices still indicated the existence of high PTH bone activity [7] . Some patients of Andress et al, however, had signs of worsening bone aluminum retention during i.v. CLT therapy. Thus, it cannot be excluded that in those patients some degree of bone aluminum deposition might have contributed to inducing a deceleration of the bone formation rate [21, 34, 36] .
Both bGLA protein and alkaline phosphatase are increased in chronic uremic patients with HBD reflecting pathologically high bone turnover rate [34] . In keeping with both bone findings and iPTH levels, both proteins were greatly raised in our subjects. Intravenous CLT therapy, along with decreases in iPTH concentrations and improvement of HBD lesions, also caused parallel decreases of both biALP and TALP to values within normal limits, These findings demonstrate that either biALP and TALP, which also includes the liver component of the enzyme, might be a useful non-invasive marker for monitoring HBD lesions during long-term CLT therapy, provided underlying chronic liver diseases are excluded. In our patients, bOLA protein showed a biphasic response, with an early increase soon after the start of i.v.
CLT therapy followed by a decrease some time later. These findings reconcile previous studies in which increases after shortterm CLT courses [37] or decreases after longer CLT treatment [38] were reported. Probably the early increase mainly reflects the direct stimulatory effects of the sterol on the bone, while the later decrease is a reflections of lessened bone PTH overactivity [37, 38] . In our patients, bGLA protein, although decreased, did not normalize. In dialyzed patients, however, bULA protein might be raised due to either increased production from high bone turnover or to decreased plasma clearance owing to lack of renal excretion [34, 38] . Either chronic hypocalcemia or decreased circulating CLT levels could be factors involved in proliferation of parathyroid cells in chronic uremia [30] . In addition to the PTH-lowering effect, therefore, chronic CLT administration could also reduce the size of already enlarged parathyroid glands. In a previous study, intraperitoneal CLT administration for four to six weeks resulted in enhanced cellular apoptosis of the parathyroids of chronically uremic rats [39] . It is still controversial whether CLT pulsed therapy might result in regression of parathyroid hyperplasia in chronic uremic humans. In fact, both decreased [40] and unchanged [41] sizes of ultrasonographically measured glands have been found after short [40] or long term [41] therapy with equivalent doses of pulsed high dose oral CLT. Adequate imaging of the parathyroid by ultrasonography is critically dependent on the operator's skill and both false-positive and falsenegative results can be due to concomitant thyroid diseases [42] .
Furthermore, repeated evaluation of the glands, such as those made in the above studies, might not reveal changes in echographically measured gland sizes when apoptotic cells have been replaced by fibrotic tissue. In the present study, to circumvent these shortcomings, we attempted to evaluate the mass of parathyroid glands by 201Tl-99Tc subtraction scintigraphy. Since thallium behaves biologically like potassium [43] , high 2OF uptake would imply a high density of biologically active cells. Thus, the results in this study, are not readily comparable to those using echography, by which the "physical" rather than the "functional" mass of parathyroids is explored.
In previous experimental studies, treatment of rats with high CLT doses before performing subtotal nephrectomy prevented the development of parathyroid hyperplasia, while ten days of this treatment started three weeks after subnephrectomy did not reduce the weight of the glands that had become hyperplastic in the meantime [44] . In the present study the parathyroid 201Tl uptake was attenuated three to four months after starting i.v. CLT treatment, and was significantly lowered eight months after the treatment began. Thus, this lessened uptake of the tracer in our patients could be due to either a generalized decrease of the biological activity of their parathyroid cells or to a reduction of their absolute numbers. From these findings it can be inferred that high doses of CLT might lead to regression of parathyroid cellular hyperplasia, provided enough time is allowed to elapse after starting the therapy.
To conclude, in the present study, long-term treatment with high i.v. CLT doses of a group of hemodialyzed uremics with proven secondary hyperparathyroidism resulted in decreases of iPTH to levels which are comparable to those of patients with mild or no HBD [20] . Furthermore, the histomorphometric indices of HBD improved in all patients, with normalization in some of them, while biALP nearly normalized. Finally, imaging studies of the parathyroids gave evidence of reduction of the functional mass of the glands. Taken together, these findings are evidence of healing of HBD in our subjects. Careful monitoring of these patients is mandatory in order to avoid excess CLT dosing, which could lead to low-dynamic metabolic bone disease [34] .
Studies are currently underway in our center to identify the lowest i.v. CLT dose required to maintain this state of euparathyroidism, once the hyperparathyroidism has been reversed.
